Name

Galaxy Scientific

Legal name

Galaxy Brain Scientific Inc.

Website

https://galaxy-scientific.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Neuroimaging Technology

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Functional neuroimaging
• Neurology medical devices
• Brain circuit analysis
• Parkinson's diagnostics
• Precision neuroscience

Headquarters

HQ city

Nashua

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Core offering

Galaxy Scientific (legal name Galaxy Brain Scientific Inc.) develops a proprietary precision brain functional sequencing (pBFS) technology platform for precision functional neuroimaging analysis used to identify brain circuit dysfunctions underlying neurological disorders. The company is also developing Class III medical devices for treating Parkinson's disease and has initiated a pivotal registration trial.

Product overview

Galaxy Scientific is a neurotechnology company offering proprietary pBFS (precision brain functional sequencing) technology for precision functional neuroimaging. The company operates as a technology platform provider and is developing Class III medical devices for treating neurological conditions. The pBFS technology platform enables advanced neuroimaging analysis used in research and clinical applications for understanding brain circuit dysfunction.

Differentiator

Problem solved

Functional benefit

Products and services

• pBFS Technology Platform Proprietary precision brain functional sequencing (pBFS) technology platform that enables precision functional neuroimaging analysis for identifying brain circuit dysfunctions underlying neurological disorders, primarily Parkinson's disease. Used by healthcare providers and neuroscience research institutions.
• Class III Medical Device for Parkinson's Disease Class III medical device under development for treating Parkinson's disease, targeting the SCAN-deep brain region connectivity abnormality identified as the core mechanism of the disease.

Quantifiable outcome

• Identified SCAN-deep brain region connectivity abnormality as core Parkinson's disease mechanism, applicable to all existing effective therapies

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• NeuroPace: NeuroPace develops the RNS (Responsive Neurostimulation) System, a Class III implantable neuro device for epilepsy, paralleling Galaxy Scientific's Class III device path for Parkinson's disease and making it the closest peer in regulatory and clinical execution model.
• Renishaw: Renishaw's Neuromate stereotactic robotic system is used for DBS electrode placement and other functional neurosurgery procedures, overlapping with Galaxy Scientific's precision neuroscience device focus and target clinical workflows for Parkinson's treatment.
• Brainlab: Brainlab provides neurosurgical planning and functional neuroimaging software platforms used in DBS targeting and brain mapping, making it the closest software-platform peer to Galaxy Scientific's precision functional neuroimaging offering for brain circuit analysis.

Broad incumbents

• Boston Scientific: Boston Scientific's Vercise DBS system targets Parkinson's disease and other movement disorders and includes imaging-guided programming features, putting it in direct competition with Galaxy Scientific's precision functional neuroimaging approach to Parkinson's therapy.
• Medtronic: Medtronic is the global leader in deep brain stimulation (DBS) for Parkinson's disease through its Activa system, with the largest installed base, clinical evidence, and commercial infrastructure in the Parkinson's neuromodulation market that Galaxy Scientific is targeting with its Class III device and SCAN-based approach.
• Abbott: Abbott (via St. Jude Medical) markets the Infinity DBS system for Parkinson's disease and other movement disorders, making it a direct incumbent competitor in next-generation Parkinson's neuromodulation and a potential partner or acquirer for any precision-neuroimaging-enabled device platform.

Emerging players

• Functional Neuromodulation: Functional Neuromodulation is a venture-backed developer of DBS systems specifically targeting early-stage Alzheimer's disease, representing an emerging peer in disease-targeted, brain-circuit-based neuromodulation that parallels Galaxy Scientific's indication-specific device approach.
• Insightec: Insightec develops MR-guided focused ultrasound (Exablate Neuro) for movement disorders including Parkinson's tremor, representing an emerging non-invasive alternative in the same Parkinson's device therapy market Galaxy Scientific is targeting with its Class III SCAN-based approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/GalaxyScientifc
• LinkedInlinkedin.com/company/galaxy-scientific

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galaxy Scientific